CR20110305A - Péptidos antagonistas de crhr2 y usos de estos - Google Patents

Péptidos antagonistas de crhr2 y usos de estos

Info

Publication number
CR20110305A
CR20110305A CR20110305A CR20110305A CR20110305A CR 20110305 A CR20110305 A CR 20110305A CR 20110305 A CR20110305 A CR 20110305A CR 20110305 A CR20110305 A CR 20110305A CR 20110305 A CR20110305 A CR 20110305A
Authority
CR
Costa Rica
Prior art keywords
antagonist peptides
crhr2
crhr2 antagonist
peptides
corticotropin
Prior art date
Application number
CR20110305A
Other languages
English (en)
Inventor
Ronald V Swanson
Nigel P Shankley
Veronica Moreno
Peter Gengo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20110305A publication Critical patent/CR20110305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)

Abstract

La presente invención se relaciona con péptidos nuevos que son antagonistas selectivos del receptor de la hormona de liberación de corticotropina tipo 2 (CRHR2) y las composiciones de éstos para el tratamiento, mejora o inhibición de afecciones cardiovasculares.
CR20110305A 2008-11-04 2011-06-06 Péptidos antagonistas de crhr2 y usos de estos CR20110305A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11123308P 2008-11-04 2008-11-04
US17889009P 2009-05-15 2009-05-15

Publications (1)

Publication Number Publication Date
CR20110305A true CR20110305A (es) 2011-11-10

Family

ID=41509080

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110305A CR20110305A (es) 2008-11-04 2011-06-06 Péptidos antagonistas de crhr2 y usos de estos

Country Status (20)

Country Link
US (1) US10040838B2 (es)
EP (1) EP2362881B1 (es)
JP (1) JP2012508014A (es)
KR (1) KR20110091720A (es)
CN (1) CN102272151B (es)
AU (1) AU2009313619A1 (es)
BR (1) BRPI0921640A2 (es)
CA (1) CA2742710A1 (es)
CO (1) CO6341479A2 (es)
CR (1) CR20110305A (es)
EA (1) EA201170647A1 (es)
EC (1) ECSP11011099A (es)
ES (1) ES2723098T3 (es)
IL (1) IL212685A0 (es)
MX (1) MX2011004718A (es)
NI (1) NI201100087A (es)
NZ (1) NZ592670A (es)
SG (1) SG171957A1 (es)
WO (1) WO2010053990A2 (es)
ZA (1) ZA201104160B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040838B2 (en) 2008-11-04 2018-08-07 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
WO2013123094A2 (en) 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006666A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JP3693671B2 (ja) * 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
IL154553A0 (en) * 2001-03-15 2003-09-17 Res Dev Foundation Urocortin-iii and uses thereof
US20030064052A1 (en) 2001-05-21 2003-04-03 Ponwell Enterprises, Ltd. Compositions for protein delivery via the pulmonary route
AU2002351214B2 (en) * 2001-12-03 2008-09-11 Metabolex, Inc. Methods and reagents for diagnosis and treatment of diabetes
CN100480267C (zh) * 2002-01-16 2009-04-22 宝洁公司 促肾上腺皮质激素释放因子2受体激动剂
US6936585B2 (en) 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2322569B1 (en) 2003-10-09 2020-08-26 Ambrx, Inc. Polymer derivatives for the selective modification of proteins
EP1768686A4 (en) * 2004-06-12 2007-11-14 Bayer Pharmaceuticals Corp PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
EP2114437A2 (en) 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JP2010527989A (ja) 2007-05-25 2010-08-19 ネウトロン リミテッド 半減期が延長されたｃｒｆ複合体
AU2008297874A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of secretin and optionally urodilatin as therapeutic agents
DE112008002458T5 (de) 2007-09-14 2011-06-01 Basf Plant Science Gmbh Pflanzen mit erhöhten ertragsbezogenen Eigenschaften und Verfahren zur Herstellung derselben
US10040838B2 (en) 2008-11-04 2018-08-07 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
WO2011041897A1 (en) 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
CA2842180C (en) 2011-07-18 2020-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting polyomavirus-associated pathology

Also Published As

Publication number Publication date
NI201100087A (es) 2011-10-25
AU2009313619A1 (en) 2010-05-14
ECSP11011099A (es) 2011-07-29
CO6341479A2 (es) 2011-11-21
CN102272151B (zh) 2014-08-20
SG171957A1 (en) 2011-07-28
MX2011004718A (es) 2011-07-28
CA2742710A1 (en) 2010-05-14
IL212685A0 (en) 2011-07-31
JP2012508014A (ja) 2012-04-05
EA201170647A1 (ru) 2011-12-30
NZ592670A (en) 2013-01-25
US20100130424A1 (en) 2010-05-27
ES2723098T3 (es) 2019-08-21
WO2010053990A3 (en) 2010-07-01
CN102272151A (zh) 2011-12-07
BRPI0921640A2 (pt) 2019-09-24
ZA201104160B (en) 2012-11-28
EP2362881A2 (en) 2011-09-07
EP2362881B1 (en) 2019-03-13
KR20110091720A (ko) 2011-08-12
WO2010053990A2 (en) 2010-05-14
US10040838B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
ECSP18002929A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
CR20130214A (es) Antagonistas del receptor del cgpr de piperidinona carboxamida azaindano
ECSP11011019A (es) Antagonistas del receptor de orexina de isonicotinamida
CL2017002122A1 (es) Heterociclos bicíclicos como inhibidores de fgfr4
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
UY31619A1 (es) Compuestos espiro como antagonistas del receptor npy y5
DE602007006961D1 (de) Cgrp-rezeptorantagonisten
ECSP088804A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CR20140312A (es) 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
GT201000376A (es) Compuestos organicos
UY32152A (es) Antagonistas de heteroarilo de receptores de prostaglandina d2
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
CL2011001578A1 (es) Anticuerpo que inhibe selectivamente al receptor del peptido relacionado al gen de la calcitonina ( cgrp r) humano; polinucleotido que lo codifica; vector; celula; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un medicamento para tratar una condicion asociada con cgrp r en un paciente, como migraña.
UY32820A (es) Composiciones dermatologicas de antagonistas del receptor dp2
BR112014015910A8 (pt) composição
BR112014015905A8 (pt) composição
GT200600255A (es) Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1a
CR20110305A (es) Péptidos antagonistas de crhr2 y usos de estos
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)